Keytruda for Melanoma: What the Decision Means

In October 2026, the NNGYK approved a streamlined procedure for the preoperative, or neoadjuvant, use of Keytruda, whose active substance is pembrolizumab, in malignant melanoma. According to the official information, the measure simplifies the bureaucratic process associated with off-label prescribing for doctors and patients.

The decision does not mean that an entirely new cancer drug has just been introduced in Hungary. Keytruda is already an established immunotherapy medicine; the change concerns the procedure for using it before melanoma surgery. The treating doctor will still decide whether to use the medicine based on the patient’s condition and medical considerations.

What does the streamlined procedure mean?

Medicines are authorised for specific diseases, patient groups and treatment settings. If a doctor intends to use a medicine differently or at another stage of treatment, this may be considered off-label prescribing, which is subject to a separate procedure.

The NNGYK’s decision simplifies this administrative route for the preoperative use of Keytruda in malignant melanoma. Based on the authority’s information, the same individual authorisation process will therefore not have to be carried out separately for every patient concerned. This is primarily a procedural change: it does not replace oncological assessment and does not in itself make the treatment suitable for every melanoma patient.

The change may also reduce doctors’ administrative burden. In practical terms, this could mean that less paperwork is required before a treatment considered medically justified can be prescribed. However, simplifying the procedure is not the same as automatically prescribing the medicine or guaranteeing that it will be covered by social health insurance.

What is neoadjuvant treatment?

Neoadjuvant treatment describes the timing of cancer therapy: the patient receives drug treatment before the planned surgery. This differs from adjuvant therapy, which is administered after surgery. The two approaches occupy different places in the treatment plan and therefore cannot automatically be substituted for one another.

During preoperative treatment, the medical team can also monitor how the tumour responds to the therapy. However, whether neoadjuvant use is appropriate may depend on factors including the extent of the disease, the tumour’s characteristics, the patient’s general condition and the planned surgery. The decision therefore usually requires cooperation between several medical specialties.

Importantly, the term neoadjuvant does not refer to a new active substance or a separate class of medicines. The same medicine is used at a different point in the treatment of the disease. The change in Hungary relates specifically to this preoperative treatment setting.

How does pembrolizumab work?

Cancer immunotherapy does not work directly on the same principle as conventional cytotoxic treatments. Its aim is to help the immune system recognise and attack cancer cells. Pembrolizumab belongs to a class of medicines known as immune checkpoint inhibitors.

The immune system uses inhibitory mechanisms to prevent excessive activity and avoid unnecessarily damaging the body’s own tissues. Some tumours can exploit these brakes, thereby reducing the immune response against them. According to Egészségvonal’s information on cancer immunotherapy, pembrolizumab is a PD-1 inhibitor: by blocking this pathway, it may help T cells recognise and destroy cancer cells.

This does not mean that immunotherapy produces the same outcome for everyone. Treatment response and side effects may vary between patients. Because these medicines affect immune function, adverse reactions can also affect different organs, so treatment requires specialist supervision and regular monitoring.

Not an automatic treatment for every melanoma patient

The general term melanoma is not sufficient on its own to select a treatment. The treating doctor must consider the stage and extent of the disease, the patient’s general condition, any coexisting conditions and the interventions being planned. The streamlined procedure therefore creates an option, but does not constitute a general treatment recommendation.

The procedural decision also does not mean that surgery becomes unnecessary. The term neoadjuvant therapy specifically indicates that drug treatment precedes the planned surgical procedure. The exact treatment sequence is determined by weighing oncological and surgical considerations together.

For the patient, the most important question is therefore not whether the medicine is generally available, but whether its preoperative use may be appropriate and safe in their particular case. Only the specialist team providing treatment can give a personalised answer.

Authorisation and funding are not the same

The professional and regulatory conditions for prescribing a medicine and social health insurance coverage of treatment costs are two separate issues. The streamlined procedure simplifies administrative authorisation, but this alone does not mean that every patient concerned will automatically receive funding in the new treatment setting.

According to a report by Zsaruhírek, in cases where there is no automatic social health insurance coverage, an individual request for equitable funding may be required from the National Health Insurance Fund of Hungary. As this information comes from a secondary source, patients should ask their healthcare provider or the National Health Insurance Fund about the funding conditions that apply to their case.

Simplifying the procedure therefore does not automatically remove every barrier to access. Before treatment can begin, the prescribing, institutional and funding requirements must also be met, in addition to medical eligibility. These should be clarified separately because satisfying one condition does not necessarily resolve the others.

What should patients ask their doctor?

The decision becomes tangible for patients when the oncology team considers the preoperative use of pembrolizumab as part of a specific treatment plan. During the consultation, it may be useful to clarify several distinct questions:

• Why is preoperative immunotherapy being considered in this case?
• What is the aim of the treatment, and how will the tumour’s response be monitored?
• What side effects may occur, and which symptoms must be reported immediately?
• How might the therapy affect the timing of surgery?
• What tests and monitoring will be required?
• Has funding been arranged, or is further administration required?

The essence of the NNGYK’s decision is that it provides a simpler procedural framework for the preoperative use of Keytruda against melanoma. This may represent a meaningful change in care for the appropriate patient group, but it does not constitute a universal cure, automatic treatment or guaranteed funding in every case. This article provides general information and does not replace a personal consultation with an oncologist or healthcare provider.